Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
AG Ellison settles with Novo Nordisk to cap out-of-pocket payments for insulin at $35 a month
Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.
Novo Nordisk insulin now $35 per month for Minnesotans thanks to Attorney General Keith Ellison
Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Novo Norodisk caps insulin prices at $35 for Minnesotans
If you rely on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday.
Ozempic, Novo Nordisk and type 2 diabetes
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.
1d
Fact Check: Message about insulin price increase announcements originated as satire
A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...
5d
on MSN
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Crash at Reagan airport
Los Angeles wildfire updates
Gets 11 years in prison
Ex-FDNY chief pleads guilty
Lay's potato chips recall
FDA upgrades recall
OK school citizenship rule
Denver schools face probe
Security detail revoked
ICC sanctions bill blocked
Approved for kidney disease
CO military base for ICE use
1st Latina, Black AZ justice
Bird flu 'widespread' in MA
Pushes for earlier trial
Agrees to settle Trump suit
'The Voice' alum dies at 44
Witkoff meets Netanyahu
Drops classified docs case
To hold migrants
To lay off 234 workers
OpenAI probing DeepSeek
NC inmate escapes
Recalls chicken nuggets
Rescinds freeze on grants
Email privacy lawsuit filed
To recall 290K+ vehicles
Cutting corporate workforce
Fall behind in reading
Record trade deficit in goods
Signs Laken Riley Act
Related topics
Minnesota
United States
Ozempic
Eli Lilly and Company
Sanofi
Feedback